79374502 - AFFIBODY

Information

• Trademark
• 79374502

• Source

• Serial Number

  79374502

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 10 - Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  March 31, 2023
  2 years ago

• Transaction Date

  April 03, 2025
  3 days ago

• Status Date

  March 19, 2025
  18 days ago

• Published for Opposition Date

  April 08, 2025
  a day from now

• Location Date

  March 19, 2025
  18 days ago

• Status Code

  681

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  SWIFT, GILBERT

• Attorney Docket Number

  1040TM200683

  Attorney Name

  Jessica S. Sachs

  Law Office Assigned Location Code

  L90

• Owners

  • AFFIBODY AB

Case File Statements

• DM0000: The mark consists of the black wording, "AFFIBODY" at right; the blue design of three solid circles over a solid, curved band appears at left; the color white represents background, outlining, shading and/or transparent areas and is not part of the mark.
• GS0051: Medical and veterinary substances, preparations and articles, namely, Medical diagnostic reagents and assays for testing of bodily fluids, Clinical diagnostic reagents for medical use, Diagnostic biomarker reagents for medical purposes, Diagnostic reagents and agents for medical diagnostic use, Diagnostic reagents for clinical laboratory use, Reagents for use in medical genetic testing, Radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer, contrast media for use with imaging medical equipment; pharmaceutical preparations and substances, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of neoplasms, cancer diseases, inflammatory eye, skin, muscle and joint diseases and disorders, diseases and disorders of the immune system, autoimmune diseases and disorders, local and systemic bacterial infections, viral infections, fungal infections, central nervous system (CNS) diseases, circulatory system, respiratory system, respiratory diseases and disorders, cardiovascular diseases, renal diseases, liver diseases, skin diseases, diseases of the digestive system, gastro-intestinal diseases, eye diseases and conditions, diseases of the musculoskeletal system or connective tissue; pharmaceutical preparations and substances, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of diseases and disorders of the peripheral nervous system, namely cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies and plexopathies, diseases of the blood or blood forming organs; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of disorders of the lymphatic systems namely Lymphangitis, Lymphocytosis, and Mesenteric lymphadenitis; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of metabolic diseases namely obesity, diabetes, metabolic syndrome, inborn errors of metabolism, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of diseases of the endocrine system, namely glucose homeostasis disorders, thyroid disorders, calcium homeostasis disorders and metabolic bone disease, pituitary gland disorders, sex hormone disorders and tumours of the endocrine glands; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of diseases of the genitourinary system, namely prostate, reproductive and urological diseases and disorders; diagnostic preparations and materials for medical purposes; medical therapeutic agents for regulation of biological functions, protein inhibition or activation, weight control and appetite suppression; reagents for medical, surgical, veterinary and dental use; biochemical biomarkers for medical use; diagnostic biomarker reagents for medical purposes; sanitary preparations for medical purposes
• CC0000: The color(s) black and blue is/are claimed as a feature of the mark.
• GS0011: Chemical substances and materials for industrial, scientific and laboratory use other than for medical or veterinary purposes; chemical reagents other than for medical or veterinary purposes, biochemical preparations for scientific purposes; biochemical substances for scientific purposes; chemical substances for use in the production of drugs, pharmaceuticals and antibodies; reagents for scientific, laboratory, analysis, research, medical research, testing, inspection, detecting or verification use other than for medical or veterinary purposes; reagents for use in the development of antibodies other than for medical or veterinary purposes; reagents for use in scientific apparatus for chemical or biological analysis other than for medical or veterinary purposes; antibodies and antibodies-based chemicals, except for medical or veterinary use
• GS0441: Human healthcare services; medical services; providing medical information; physical examination; medical diagnostic testing, monitoring and reporting services; optical medical imaging for medical diagnostic use; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical testing for diagnostic or treatment purposes
• GS0101: Medical and veterinary apparatus and instruments, namely, medical apparatus and instruments for use in surgery, chromatography media in the nature of liquid chromatography apparatus for medical use in medical research; diagnostic, examination, and monitoring equipment namely, medical apparatus and instruments for diagnostic radiopharmaceutical use; screening apparatus and instruments for medical purposes, namely, ultrasonic medical diagnostic apparatus; separation instruments for medical use, namely, tubing and valve assembly set and electromechanical fluidic instrument, and other similar or related devices, which process human whole blood for the purpose of separating human blood components for use in blood transfusions and washing human red blood cells with clinical medical reagents for use in blood transfusions chromatography columns for use in affinity separation, chromatography media for use in affinity separation; gas chromatographic instruments for medical use; diagnostic imaging apparatus for medical use; medication fluid injectors
• GS0421: Scientific research, technological research, product development and design in the field of biotechnics and diagnostics; medical and pharmacological research services for medical purposes in the field of biotechnics and diagnostics; medical, pharmaceutical and biotechnological laboratory research services for medical purposes in the field of biotechnics and diagnostics; scientific investigations for medical purposes; medical and scientific research, namely, conducting clinical trials for others; providing scientific information about the results of clinical trials for pharmaceutical products; scientific advisory services relating to diagnostic preparations; biochemical analysis and research for medical purposes in the field of biotechnics and diagnostics; drug discovery services; pharmaceutical products development and evaluation

Case File Event Statements

• 7/20/2023 - a year ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR

• 1/11/2024 - a year ago

  8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 7/21/2023 - a year ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 7/25/2023 - a year ago

  3 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 12/27/2023 - a year ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 12/28/2023 - a year ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 12/29/2023 - a year ago

  6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 1/31/2024 - a year ago

  9 - REFUSAL PROCESSED BY IB Type: RFNT

• 7/9/2024 - 9 months ago

  12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 7/9/2024 - 9 months ago

  11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 7/9/2024 - 9 months ago

  10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 9/11/2024 - 6 months ago

  13 - FINAL REFUSAL WRITTEN Type: CNFR

• 1/11/2024 - a year ago

  7 - REFUSAL PROCESSED BY MPU Type: RFRR

• 9/11/2024 - 6 months ago

  14 - FINAL REFUSAL E-MAILED Type: GNFR

• 9/11/2024 - 6 months ago

  15 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN

• 9/16/2024 - 6 months ago

  16 - SUBSEQUENT FINAL REFUSAL WRITTEN Type: CFRC

• 12/18/2024 - 3 months ago

  19 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR

• 9/16/2024 - 6 months ago

  17 - SUBSEQUENT FINAL EMAILED Type: GNSF

• 9/16/2024 - 6 months ago

  18 - NOTIFICATION OF SUBSEQUENT FINAL EMAILED Type: GNS1

• 1/4/2025 - 3 months ago

  21 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX

• 3/5/2025 - a month ago

  23 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 12/18/2024 - 3 months ago

  20 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS

• 3/5/2025 - a month ago

  24 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 3/13/2025 - 24 days ago

  26 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 3/13/2025 - 24 days ago

  28 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 3/13/2025 - 24 days ago

  25 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 3/5/2025 - a month ago

  22 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR

• 3/13/2025 - 24 days ago

  27 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 3/13/2025 - 24 days ago

  29 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 4/2/2025 - 4 days ago

  30 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP